Format
Sort by

Send to

Choose Destination

Search results

Items: 16

1.

Cardiovascular disease after cancer therapy.

Aleman BM, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, Vrieling C, Darby SC.

EJC Suppl. 2014 Jun;12(1):18-28. doi: 10.1016/j.ejcsup.2014.03.002. Epub 2014 May 29.

2.

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups.

Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25500422
3.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology; European Society of Medical Oncology.

Breast. 2014 Oct;23(5):489-502. doi: 10.1016/j.breast.2014.08.009. Epub 2014 Sep 20. No abstract available.

4.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E.

Ann Oncol. 2014 Oct;25(10):1871-88. doi: 10.1093/annonc/mdu385. Epub 2014 Sep 18. No abstract available.

5.
6.

Recommendations for the aesthetic evaluation of breast cancer conservative treatment.

Cardoso MJ, Cardoso JS, Vrieling C, Macmillan D, Rainsbury D, Heil J, Hau E, Keshtgar M.

Breast Cancer Res Treat. 2012 Oct;135(3):629-37. doi: 10.1007/s10549-012-1978-8. Epub 2012 Feb 4. Review.

PMID:
22307267
7.

Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.

Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, Bartelink H; EORTC Radiation Oncology Group.

Eur J Cancer. 2008 Nov;44(17):2587-99. doi: 10.1016/j.ejca.2008.07.032. Epub 2008 Aug 29. Erratum in: Eur J Cancer. 2009 Jul;45(11):2061.

PMID:
18757193
8.

Docetaxel in the management of patients with head and neck squamous cell carcinoma.

Bernier J, Vrieling C.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1023-32. doi: 10.1586/14737140.8.7.1023. Review.

PMID:
18588449
9.

Long-term results of stomach-conserving therapy in gastric MALT lymphoma.

Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM.

Radiother Oncol. 2008 Jun;87(3):405-11. doi: 10.1016/j.radonc.2008.02.012. Epub 2008 Mar 17.

PMID:
18343513
10.

Is face-only photographic view enough for the aesthetic evaluation of breast cancer conservative treatment?

Cardoso MJ, Magalhães A, Almeida T, Costa S, Vrieling C, Christie D, Johansen J, Cardoso JS.

Breast Cancer Res Treat. 2008 Dec;112(3):565-8. doi: 10.1007/s10549-008-9896-5. Epub 2008 Jan 18.

PMID:
18204895
11.

Turning subjective into objective: the BCCT.core software for evaluation of cosmetic results in breast cancer conservative treatment.

Cardoso MJ, Cardoso J, Amaral N, Azevedo I, Barreau L, Bernardo M, Christie D, Costa S, Fitzal F, Fougo JL, Johansen J, Macmillan D, Mano MP, Regolo L, Rosa J, Teixeira L, Vrieling C.

Breast. 2007 Oct;16(5):456-61. Epub 2007 Jul 2.

PMID:
17606373
12.

Factors determining esthetic outcome after breast cancer conservative treatment.

Cardoso MJ, Cardoso J, Santos AC, Vrieling C, Christie D, Liljegren G, Azevedo I, Johansen J, Rosa J, Amaral N, Saaristo R, Sacchini V, Barros H, Oliveira MC.

Breast J. 2007 Mar-Apr;13(2):140-6.

PMID:
17319854
13.

Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?

Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H; EORTC Radiotherapy, Breast Cancer Groups.

Eur J Cancer. 2003 May;39(7):932-44.

PMID:
12706362
14.

The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.

Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H.

Radiother Oncol. 2000 Jun;55(3):219-32.

PMID:
10869738
15.

The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85.

PMID:
10524422
16.

Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, Pierart M, Poortmans PM, Struikmans H, Van der Schueren E, Van Dongen JA, Van Limbergen E, Bartelink H.

Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76.

PMID:
10524421
Items per page

Supplemental Content

Loading ...
Write to the Help Desk